Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells.
Fusion of BERH-2 rat hepatocellular carcinoma cells with activated B cells produced hybrid cells that lost their tumorigenicity and became immunogenic. Syngeneic rats injected with BERH-2-B hybrid cells became resistant to challenge with parental BERH-2 cells, and rats with established BERH-2 hepatomas were cured by subsequent injection of BERH-2-B cells. Both CD4+ and CD8+ cells were essential for the induction of protective immunity; however, only CD8+ cells were required for the eradication of BERH-2 tumors. The generation of hybrid tumor cells that elicit antitumor immune responses may be a useful strategy for cancer immunotherapy.
Guo
Y
Y
Tumor Immunology and Biotherapy Center, Eastern Institute of Hepatobiliary Surgery, Shanghai, China.
Wu
M
M
Chen
H
H
Wang
X
X
Liu
G
G
Li
G
G
Ma
J
J
Sy
M S
MS
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology*; D018122:B7-1 Antigen / Q000032:analysis; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002459:Cell Fusion; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006822:Hybrid Cells / Q000276:immunology*; D016233:Immunotherapy, Active; D008114:Liver Neoplasms, Experimental / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D008213:Lymphocyte Activation; D009368:Neoplasm Transplantation; D051381:Rats; D017208:Rats, Wistar; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014407:Tumor Cells, Cultured; D014611:Vaccination; D014612:Vaccines / Q000276:immunology*
D018122:B7-1 Antigen; D000949:Histocompatibility Antigens Class II; D014612:Vaccines